Transforming cancer care: Neoadjuvant therapy and trials in melanoma care

Neoadjuvant immunotherapy is transforming patient care in the field of melanoma. New research recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting is set to change melanoma treatment protocols globally, and likely to have significant impact on treatment for other cancers too.

In this podcast, A/Prof Matt Carlino leads an engaging discussion with MIA’s Prof Georgina Long AO, A/Prof Alex Menzies and A/Prof Alex van Akkooi as they discuss the pivotal results from the NADINA trial and how this will undoubtedly change the standard of care for Stage III melanoma patients. They also discuss the practical implications for implementing this treatment regime, including relevant patient populations, toxicity, impacts for surgery and future directions.

This podcast is suitable for Medical Oncologists, Surgical Oncologists, Pathologists, Researchers, GPs Oncology Nurses and other healthcare professionals. It is produced by Melanoma Institute Australia.

SPEAKERS

A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals | Clinical Associate Professor, The University of Sydney Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney A/Prof Alexander Menzies - Medical Oncologist, Melanoma Institute Australia and Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of Sydney A/Prof Alexander van Akkooi - Associate Professor in Melanoma Surgical Oncology, Melanoma Institute Australia and Royal Prince Alfred Hospital, The University of Sydney

PUBLICATIONS

Blank C, Lucas MW, Scolyer RA, et al. Neoadjuvant Nivolumab and Ipilimumab in

Resectable Stage III Melanoma

. N Engl J Med 2024. DOI: 10.1056/NEJMoa2402604 Patel SP, Othus M, Chen Y, et al. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med 2023;388:813-823.

FURTHER EDUCATION

Podcast: Neoadjuvant immunotherapy: Revolutionising melanoma treatment Video: The critical role of standardised pathological assessment in neoadjuvant therapy for melanoma: A guide for Pathologists Conference: 2024 Australasian Melanoma Conference

Please note that this podcast was accurate at the time of recording (2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.